Sciotec Diagnostic Technologies GmbH Report issue

For profit
Founded: Tulln Austria (2004)
Status: Acquired by STADA Arzneimittel AG (2015)

Organization Overview

First Clinical Trial
2009
NCT00916487
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sciotec Diagnostic Technologies GmbH

Active Ingredients

Drugs in Other Trials (1)

nevulose (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1